LAMASSU BIOTECH IS A PRIVATELY HELD, CLINICAL STAGE BIO-PHARMACEUTICAL COMPANY DEVELOPING AN INVESTIGATIONAL MDM2 SMALL MOLECULE INHIBITOR (SA53).
Accelerating treatment, means saving more lives. At Lamassu, our team of dedicated physicians, engineers, and translational scientists are driven by a passion to treat patients like family. Our goal is to speed the innovation process by bringing transformational treatments from concept to bedside faster than other companies. Lamassu’s patient-centric approach focuses on creating hope for patients with unmet needs, whose conditions lack currently available treatment options. Through the development of novel therapeutics and targeted strategies that ensure greater efficiency and shorter approval timeframes, we bring hope to patients facing diagnoses that currently lack treatment options. With decades of experience developing leading medical treatments, we believe that it is not only the transformative power of science, but also hope that leads to healing.
Learn more